Adverse events Adverse events included discomfort, local skin reactions, superficial infections, cold induced injuries and thrombolytic events · people undergoing total knee replacement
It is very uncertain whether any cold therapy changes total adverse eventsAdverse events included discomfort, local skin… compared with no cold therapy following total knee replacement (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people undergoing total knee replacement
It is very uncertain whether any cold therapy changes withdrawals due to adverse events compared with no cold therapy following total knee replacement (very low certainty).
1 finding from 1 review
Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications, 4 to 6 weeks · people with neovascular glaucoma
Anti‐VEGF may leads to higher proportion of participants with IOP ≤ 21 mmHg, with or without… compared with no anti‐VEGF (low certainty).
1 finding from 1 review
Mean IOP ( · people with neovascular glaucoma
It is very uncertain whether anti‐VEGF changes mean IOP, 4 to 6 weeks compared with no anti‐VEGF (very low certainty).
1 finding from 1 review
Visual acuity · people with neovascular glaucoma
It is very uncertain whether anti‐VEGF changes proportion of participants with improvement in visual acuity of 2… compared with no anti‐VEGF (very low certainty).
1 finding from 1 review
Proportion of participants with complete regression of new iris vessels, 4 to 6 weeks · people with neovascular glaucoma
Anti‐VEGF may leads to higher proportion of participants with complete regression of new iris… compared with no anti‐VEGF (low certainty).
1 finding from 1 review
Proportion of participants with relief of pain and resolution of redness, 1 year · people with neovascular glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events assessed in various ways, up to 24 months · people with neovascular glaucoma
1 finding from 1 review
no estimate extracted
6 participants
GRADE not reported
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension grade ≥ 3 · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension grade ≥ 3 · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · newly‐diagnosed EOC
It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).
1 finding from 1 review